Pregnant women with confirmed CMV infection B25
Conditions
Interventions
Group 1: Immunoglobulin Therapy for Congenital CMV Infection
Group 2: Valaciclovir Therapy for Congenital CMV Infection
Sponsors
Klinik für Frauenheilkunde und Geburtshilfe Universitätsklinikum Essen
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: • Pregnant women with confirmed CMV infection • Treatment with Valaciclovir and/or Hyperimmunoglobulin in CMV-infected pregnant women treated at the Department of Obstetrics and Gynecology, University Hospital Essen.
Exclusion criteria
Exclusion criteria: • Missing documentation regarding CMV infection or the administered therapy (Valaciclovir or HIG). • Patients who did not receive either of the two mentioned treatment options. • Patients unable to provide informed consent, if additional contact is required to obtain missing information. • Patients who explicitly object to prospective contact or do not consent to supplementary data collection. • Patients without sufficient knowledge of German or English, if qualified linguistic counseling cannot be ensured.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Incidence of congenital CMV infections: depending on the timing of infection during pregnancy and the therapy applied. -Severity of CMV infection (e.g., symptomatic vs. asymptomatic). -Incidence of severe perinatal complications (e.g., intrauterine fetal death). | — |
Secondary
| Measure | Time frame |
|---|---|
| -Time to onset of CMV infections. -Incidence of CMV-associated neurological deficits (e.g., microcephaly, hearing loss). -Impact on fetal development (e.g., growth restrictions, birth weight). | — |
Countries
Germany
Contacts
Public ContactAntonella Iannaccone
Klinik für Frauenheilkunde und Geburtshilfe Universitätsklinikum Essen
Outcome results
None listed